Search results
Results: 32
Number of items: 32
-
van Dam, K. P. J., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Busch, M. H., Verstegen, N. J. M., van Ham, S. M., Tas, S. W., & T2B! immunity against SARS-CoV-2 study group (2023). Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations. Journal of autoimmunity, 135, Article 102984. https://doi.org/10.1016/j.jaut.2022.102984
-
van Dam, K. P. J., Tas, S. W., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Busch, M. H., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2023). Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity. BMC Infectious Diseases, 23, Article 332. https://doi.org/10.1186/s12879-023-08298-6 -
Stalman, E. W., Tas, S. W., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases. Annals of the Rheumatic Diseases, 81(12), 1757-1766. https://doi.org/10.1136/ard-2022-222904
-
Boekel, L., Besten, Y. R., Hooijberg, F., Wartena, R., Steenhuis, M., Vogelzang, E., Leeuw, M., Atiqi, S., Tas, S. W., Lems, W. F., van Ham, S. M., Eftimov, F., Stalman, E. W., Wieske, L., Kuijpers, T. W., Voskuyl, A. E., van Vollenhoven, R. F., Gerritsen, M., Krieckaert, C., ... Wolbink, G. (2022). SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period. The Lancet. Rheumatology, 4(11), e747-e750. https://doi.org/10.1016/S2665-9913(22)00221-1
-
Boekel, L., Tas, S. W., Takkenberg, R. B., Bemelman, F. J., de Wit, J., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. The Lancet. Rheumatology, 4(6), e417-e429. https://doi.org/10.1016/S2665-9913(22)00102-3
-
Wieske, L., Tas, S. W., Takkenberg, R. B., Verstegen, N. J. M., Zwinderman, K. A. H., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. The Lancet. Rheumatology, 4(5), e338-e350. https://doi.org/10.1016/S2665-9913(22)00034-0
-
Verstegen, N. J. M., Hagen, R. R., van den Dijssel, J., Kuijper, L. H., Kreher, C., Ashhurst, T., Kummer, L. Y. L., Steenhuis, M., Duurland, M., de Jongh, R., de Jong, N., van der Schoot, C. E., Bos, A. V., Mul, E., Kedzierska, K., van Dam, K. P. J., Stalman, E. W., Boekel, L., Wolbink, G., ... T2B! immunity against SARS-CoV-2 study group (2022). Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273. eLife, 11, Article e77969. https://doi.org/10.7554/eLife.77969
Page 2 of 4